Theratechnologies develops therapies for unmet medical needs in commercially attractive specialty markets.

Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets.

Special Announcement

THERATECHNOLOGIES ANNOUNCES THE CONCLUSION OF THE STRATEGIC REVIEW

October 29, 2008

Visit our media room for more information

In the clinic

Tesamorelin Phase 3 Results

Find out more on the study

 

 

Products

Our lead product: tesamorelin

Antiretrovirals have increased the life expectancy of HIV patients. Despite the benefits of these therapies, they are associated with side-effects such as lipodystrophy. We are currently studying the effects of tesamorelin (TH9507) on excessive visceral fat, an important characteristic of HIV-associated lipodystrophy. More...

Investors

See our investor kit:

2007 Annual Report

Quarterly report

First scientific symposium, sponsored by Theratechnologies, at the 11th European AIDS Conference.

Access the symposium's webcast


 

News

  • November 13, 2008 - Theratechnologies: Last patient treated in the extension phase of the confirmatory study testing tesamorelin in HIV-associated lipodystrophy More...
  • November 6, 2008 - Theratechnologies presents additional results from its tesamorelin Phase 3 studies at the 10th International workshop on adverse drug reactions and lipodystrophy in HIV More...
  • October 29, 2008 - Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States More...

Events

  • From October 1 to 3, 2008 - BioContact Québec More...
  • From September 22 to 25, 2008 - UBS Global Life Sciences Conference More...
  • August 14, 2008 - 28th Annual Canaccord Adams Global Growth Conference More...